


**ABSTRACT OF THE DISCLOSURE**

The specification discloses compounds selected from those of formula (I):



or a racemic form, isomer, N-oxide, or pharmaceutically acceptable salt thereof, wherein

5  $R_2$ ,  $m$ ,  $A$ ,  $Z_1$ ,  $n$ ,  $G_2$ ,  $X_1$ ,  $X_2$ ,  $X_3$ ,  $G_1$ , and  $R_1$  are as defined in the specification, wherein the compound of formula (I) is not 6-(2,4-dioxo-3,4-dihydro-2H-1,3-benzothiazine)-benzoate, 6-phenylthio-2,4-dioxo-3,4-dihydro-2H-1,3-benzothiazine, 6-benzylsulphonyl-2,4-dioxo-3,4-dihydro-2H-1,3-benzothiazine, 6-benzophenone-2,4-dioxo-3,4-dihydro-2H-1,3-benzothiazine or 6-(2,4-dihydroxy)-benzophenone-2,4-dioxo-3,4-dihydro-2H-1,3-

10 benzothiazine. The specification also discloses processes for preparing the compounds, pharmaceutical compositions comprising said compounds of formula (I) or a racemic form, isomer, N-oxide, or pharmaceutically acceptable salt thereof, and methods of treating diseases or disorders mediated by a MMP-13 enzyme or responsive to treatment with an inhibitor of a MMP-13 enzyme, comprising administering said compounds of formula (I)

15 or a racemic form, isomer, N-oxide, or pharmaceutically acceptable salt thereof.